| __timestamp | Sarepta Therapeutics, Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 49315000 | 91733000 |
| Thursday, January 1, 2015 | 75043000 | 87644000 |
| Friday, January 1, 2016 | 83749000 | 92365000 |
| Sunday, January 1, 2017 | 122682000 | 85656000 |
| Monday, January 1, 2018 | 207761000 | 88196000 |
| Tuesday, January 1, 2019 | 284812000 | 89971000 |
| Wednesday, January 1, 2020 | 317875000 | 93413000 |
| Friday, January 1, 2021 | 282660000 | 91355000 |
| Saturday, January 1, 2022 | 451421000 | 113676000 |
| Sunday, January 1, 2023 | 481871000 | 198366000 |
| Monday, January 1, 2024 | 218935000 |
In pursuit of knowledge
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Sarepta Therapeutics, Inc. and Taro Pharmaceutical Industries Ltd. have taken different paths in optimizing these costs. From 2014 to 2023, Sarepta's SG&A expenses surged by over 870%, peaking in 2023, while Taro's expenses grew by approximately 116% during the same period. This stark contrast highlights Sarepta's aggressive expansion strategy, reflected in its rising costs, compared to Taro's more conservative approach. Interestingly, Taro's expenses remained relatively stable until a notable increase in 2023, suggesting a strategic shift. As the industry evolves, these trends offer insights into how companies balance growth with cost management. Missing data for 2024 suggests ongoing developments, making it a pivotal year to watch.
Pfizer Inc. and Sarepta Therapeutics, Inc.: SG&A Spending Patterns Compared
Vertex Pharmaceuticals Incorporated vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
Genmab A/S or Sarepta Therapeutics, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Pharming Group N.V.
Breaking Down SG&A Expenses: Sarepta Therapeutics, Inc. vs Ultragenyx Pharmaceutical Inc.
Sarepta Therapeutics, Inc. vs Catalyst Pharmaceuticals, Inc.: SG&A Expense Trends
Sarepta Therapeutics, Inc. vs Veracyte, Inc.: SG&A Expense Trends
CRISPR Therapeutics AG or Taro Pharmaceutical Industries Ltd.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: PTC Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd. Trends and Insights
Who Optimizes SG&A Costs Better? MorphoSys AG or Taro Pharmaceutical Industries Ltd.
Vericel Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Mesoblast Limited vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends